Buscar en
Medicina de Familia. SEMERGEN
Toda la web
Inicio Medicina de Familia. SEMERGEN Dual antiplatelet therapy and an anemia subtype
Información de la revista
Vol. 44. Núm. 2.
Páginas e84 (Marzo 2018)
Descargar PDF
Más opciones de artículo
Vol. 44. Núm. 2.
Páginas e84 (Marzo 2018)
Letter to the Editor
DOI: 10.1016/j.semerg.2016.06.013
Acceso a texto completo
Dual antiplatelet therapy and an anemia subtype
Doble antiagregación y subtipo de anemia
L. Cerit
Department of Cardiology, Near East University Hospital, Nicosia, Cyprus
Información del artículo
Texto completo
Descargar PDF
Texto completo
To The Editor,

I have read the article entitled “Dual antiplatelet therapy and hemoglobin level: An observational study” by Quinteiro-Alonso et al.1 with great interest, recently published in Semergen 2015 Sep 18. The investigators reported that Dual antiplatelet therapy is associated with a decrease in Hb. Anemia or worsening of previous anemia appeared in about half of the subjects.1

Anemia has been defined as an independent cardiovascular risk factor; its presence portends poor outcomes in patients with coronary artery disease. It is associated with higher rates of in-hospital mortality in patients with myocardial infarction2. Anemia was classified using mean corpuscular volume as microcytic, normocytic, or macrocytic. Blood loss could result in a normocytic anemia, reflecting acute loss of blood cells along with blood volume, or a microcytic anemia due to iron deficiency in patients with chronic blood loss. Shishehbor et al.3 reported that patients with macrocytic anemia have the highest mortality after PCI compare to normocytic, and micrcytic anemia. Macrocytosis is considered a structural and functional abnormality of the erythrocyte membrane. The spectrum of etiologies associated with macrocytosis accompanied by anemia includes malnutrition, such as vitamin B12 and folate deficiency, use of chemotherapeutic and anticonvulsant agents, alcoholism with chronic liver damage4. As well as, macrocytosis is an independent predictor of adverse outcomes after PCI regardless of the presence or absence of anemia.5

In this context, it might be beneficial to evaluate adverse outcomes depending on subtypes of anemia after DES implantation.

Conflict of interest


M.P. Quinteiro-Alonso, M. González-Cao, C. Barreales-Cardín, G.J. Díaz-Grávalos.
Dual antiplatelet therapy and haemoglobin level: an observational study.
pii: S1138-3593(15)00250-6 [Epub ahead of print]
W.C. Wu, S.S. Rathore, Y. Wang, M.J. Radford, H.M. Krumholz.
Blood transfusion in elderly patients with acute myocardial infarction.
N Engl J Med, 345 (2001), pp. 1230-1236
M.H. Shishehbor, S.J. Filby, A.K. Chhatriwalla, R.D. Christofferson, A. Jain, S.R. Kapadia, et al.
Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia.
JACC Cardiovasc Interv, 2 (2009), pp. 329-336
F. Aslinia, J.J. Mazza, S.H. Yale.
Megaloblastic anemia and other causes of macrocytosis.
Clin Med Res, 4 (2006), pp. 236-241
M. Myojo, H. Iwata, T. Kohro, H. Sato, A. Kiyosue, J. Ando, et al.
Prognostic implication of macrocytosis on adverse outcomes after coronary intervention.
Atherosclerosis, 221 (2012), pp. 148-153
Copyright © 2016. Sociedad Española de Médicos de Atención Primaria (SEMERGEN)
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos